Brentuximab vedotin
AdcetrisDrag to rotate. Scroll or pinch to zoom.
An antibody that locks onto CD30, a marker found on certain lymphoma cells, carrying a potent cell-killing drug directly to the tumor and sparing healthy cells.
How it works
The drug is built from two parts joined together: an antibody that recognizes a protein called CD30 on the surface of certain lymphoma cells, and a powerful cell-killing chemical attached to it by a special chemical link. When the antibody finds and grabs onto a cancer cell, the whole package gets pulled inside the cell. Once inside, the link breaks apart and releases the cell-killing chemical exactly where it's needed, jamming the internal scaffolding the cell needs to divide.
What it’s used for
Used to treat several types of lymphoma, including Hodgkin lymphoma, both newly diagnosed and cases that have come back, and certain T-cell and B-cell lymphomas whose cancer cells carry the CD30 marker. It's given either on its own or combined with other chemotherapy drugs.
- Mechanism
- CD30-targeted antibody-drug conjugate
- Drug class
- Antibody-drug conjugate
- Therapeutic area
- Oncology